GlassScriptPhysician profile
Michelle Wrasse
NPI 1831667153
$8,432.37
in general payments reported to CMS, 2019-2025
26 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $1,242 · 2023: $2,511 · 2024: $2,206 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,112 · Education: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,111.69 |
| Education | $432.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,380.78 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,194.59 | 2022-2025 | Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $965.89 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $652.08 | 2021-2025 | |
| Pfizer INC. | $643.37 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $605.63 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $506.48 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $368.21 | 2021-2025 | |
| Almirall LLC | $241.82 | 2021-2025 | Seysara, Klisyri |
| Amgen INC. | $236.85 | 2021-2024 | Otezla |
| Galderma Laboratories, L.P. | $226.82 | 2021-2025 | Epsolay, Aklief, Oracea |
| Janssen Scientific Affairs, LLC | $194.66 | 2021-2022 | |
| Dermavant Sciences, INC. | $170.77 | 2022-2024 | Vtama |
| Incyte Corporation | $169.80 | 2022-2023 | Opzelura |
| Verrica Pharmaceuticals INC. | $144.86 | 2025 | Ycanth |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $134.28 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Regeneron Healthcare Solutions, INC. | $123.97 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $89.41 | 2023-2025 | Sotyktu |
| Organogenesis INC. | $81.64 | 2023-2025 | Puraply Wound Matrix, Cygnus Dual, Puraply |
| Sanofi-Aventis U.S. LLC | $64.95 | 2021 | |
| Revance Therapeutics, INC. | $62.21 | 2024 | Daxxify |
| Ucb, INC. | $54.99 | 2024 | |
| Merz North America, INC. | $45.89 | 2022 | |
| Mayne Pharma Commercial LLC | $30.17 | 2024 | |
| Kerecis Limited | $29.41 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Nabriva Therapeutics, Plc | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Wrasse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.